{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T05:24:43Z","timestamp":1744003483222,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,22]]},"DOI":"10.7759\/cureus.79437","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T09:11:06Z","timestamp":1740215466000},"source":"Crossref","is-referenced-by-count":1,"title":["In Silico Analysis of Saroglitazar and Ferulic Acid Binding to Human Ketohexokinase: Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)"],"prefix":"10.7759","author":[{"given":"Kalpana","family":"Tiwari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brijesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurag","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puneet","family":"Dhamija","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyan","family":"Vardhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amol","family":"Dehade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Substantial overlap between NAFLD and MASLD with comparable disease severity and non-invasive test performance: an analysis of the Indian Consortium on MASLD (ICOM-D) cohort","volume":"1","author":"De A","year":"2024","unstructured":"De A, Mehta M, Duseja A. Substantial overlap between NAFLD and MASLD with comparable disease severity and non-invasive test performance: an analysis of the Indian Consortium on MASLD (ICOM-D) cohort. J Hepatol. 2024, 1:162-4.","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MASLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam M","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, International Consensus Panel. MASLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020, 158:1999-2014.","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000360511","article-title":"Treatment of non-alcoholic fatty liver disease","volume":"32","author":"Dyson J","year":"2014","unstructured":"Dyson J, Day C. Treatment of non-alcoholic fatty liver disease. Dig Dis. 2014, 32:597-604. 10.1159\/000360511","journal-title":"Dig Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2023.100485","article-title":"From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease","volume":"65","author":"Rinella ME","year":"2024","unstructured":"Rinella ME, Sookoian S. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res. 2024, 65:100485. 10.1016\/j.jlr.2023.100485","journal-title":"J Lipid Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030883","article-title":"From NAFLD to MAFLD: definition, pathophysiological basis and cardiovascular implications","volume":"11","author":"Boccatonda A","year":"2023","unstructured":"Boccatonda A, Andreetto L, D'Ardes D, et al.. From NAFLD to MAFLD: definition, pathophysiological basis and cardiovascular implications. Biomedicines. 2023, 11:883. 10.3390\/biomedicines11030883","journal-title":"Biomedicines"},{"key":"ref6","article-title":"A review on current therapeutic approaches and novel agents for the treatment of non-alcoholic fatty liver disease (NAFLD)","volume":"13","author":"Tiwari K","year":"2024","unstructured":"Tiwari K, Kumar B, Vardhan G, Gupta A, Tiwari AK. A review on current therapeutic approaches and novel agents for the treatment of non-alcoholic fatty liver disease (NAFLD). Indian J Appl Res. 2024, 13:3.","journal-title":"Indian J Appl Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease: a global public health perspective","volume":"70","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM. Non-alcoholic fatty liver disease: a global public health perspective. J Hepatol. 2019, 70:531-44. 10.1016\/j.jhep.2018.10.033","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons","volume":"79","author":"Le MH","year":"2023","unstructured":"Le MH, Le DM, Baez TC, et al.. Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023, 79:287-95. 10.1016\/j.jhep.2023.03.040","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66458-z","article-title":"The PPAR \u03b1\/\u03b3 agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease","volume":"10","author":"Kumar DP","year":"2020","unstructured":"Kumar DP, Caffrey R, Marioneaux J, et al.. The PPAR \u03b1\/\u03b3 agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease. Sci Rep. 2020, 10:9330. 10.1038\/s41598-020-66458-z","journal-title":"Sci Rep"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal O","year":"2020","unstructured":"Goyal O, Nohria S, Goyal P, et al.. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Sci Rep. 2020, 10:21117.","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2174\/13894501113149990199","article-title":"The first approved agent in the Glitazar's class: saroglitazar","volume":"15","author":"Agrawal R","year":"2014","unstructured":"Agrawal R. The first approved agent in the Glitazar's class: saroglitazar. Curr Drug Targets. 2014, 15:151-5. 10.2174\/13894501113149990199","journal-title":"Curr Drug Targets"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh S","year":"2021","unstructured":"Gawrieh S, Noureddin M, Loo N, et al.. Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial. Hepatology. 2021, 74:1809-24. 10.1002\/hep.31843","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis","volume":"19","author":"Siddiqui MS","year":"2021","unstructured":"Siddiqui MS, Idowu MO, Parmar D, et al.. A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2021, 19:2670-2. 10.1016\/j.cgh.2020.10.051","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612748","article-title":"Current therapeutical approaches targeting lipid metabolism in NAFLD","volume":"24","author":"Vitulo M","year":"2023","unstructured":"Vitulo M, Gnodi E, Rosini G, Meneveri R, Giovannoni R, Barisani D. Current therapeutical approaches targeting lipid metabolism in NAFLD. Int J Mol Sci. 2023, 24:12748. 10.3390\/ijms241612748","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2015.09.018","article-title":"Redox cycling of endogenous copper by ferulic acid leads to cellular DNA breakage and consequent cell death: a putative cancer chemotherapy mechanism","volume":"289","author":"Sarwar T","year":"2015","unstructured":"Sarwar T, Zafaryab M, Husain MA, Ishqi HM, Rehman SU, Rizvi MM, Tabish M. Redox cycling of endogenous copper by ferulic acid leads to cellular DNA breakage and consequent cell death: a putative cancer chemotherapy mechanism. Toxicol Appl Pharmacol. 2015, 289:251-61. 10.1016\/j.taap.2015.09.018","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000491755","article-title":"Antioxidant properties of ferulic acid and its possible application","volume":"31","author":"Zdu\u0144ska K","year":"2018","unstructured":"Zdu\u0144ska K, Dana A, Kolodziejczak A, Rotsztejn H. Antioxidant properties of ferulic acid and its possible application. Skin Pharmacol Physiol. 2018, 31:332-6. 10.1159\/000491755","journal-title":"Skin Pharmacol Physiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315297","article-title":"Ferulic acid and P-coumaric acid synergistically attenuate non-alcoholic fatty liver disease through HDAC1\/PPARG-mediated free fatty acid uptake","volume":"23","author":"Cui K","year":"2022","unstructured":"Cui K, Zhang L, La X, et al.. Ferulic acid and P-coumaric acid synergistically attenuate non-alcoholic fatty liver disease through HDAC1\/PPARG-mediated free fatty acid uptake. Int J Mol Sci. 2022, 23:15297. 10.3390\/ijms232315297","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/nu14122530","article-title":"Ferulic acid prevents nonalcoholic fatty liver disease by promoting fatty acid oxidation and energy expenditure in C57BL\/6 mice fed a high-fat diet","volume":"14","author":"Luo Z","year":"2022","unstructured":"Luo Z, Li M, Yang Q, et al.. Ferulic acid prevents nonalcoholic fatty liver disease by promoting fatty acid oxidation and energy expenditure in C57BL\/6 mice fed a high-fat diet. Nutrients. 2022, 14:2530. 10.3390\/nu14122530","journal-title":"Nutrients"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.103890","article-title":"A network-based computational and experimental framework for repurposing compounds toward the treatment of non-alcoholic fatty liver disease","volume":"25","author":"Zareifi DS","year":"2022","unstructured":"Zareifi DS, Chaliotis O, Chala N, et al.. A network-based computational and experimental framework for repurposing compounds toward the treatment of non-alcoholic fatty liver disease. iScience. 2022, 25:103890. 10.1016\/j.isci.2022.103890","journal-title":"iScience"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S186726","article-title":"Ferulic acid attenuates liver fibrosis and hepatic stellate cell activation via inhibition of TGF-\u03b2\/Smad signaling pathway","volume":"12","author":"Mu M","year":"2018","unstructured":"Mu M, Zuo S, Wu RM, et al.. Ferulic acid attenuates liver fibrosis and hepatic stellate cell activation via inhibition of TGF-\u03b2\/Smad signaling pathway. Drug Des Dev Ther. 2018, 12:4107-15. 10.2147\/DDDT.S186726","journal-title":"Drug Des Dev Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi K","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, et al.. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022, 7:851-61. 10.1016\/S2468-1253(22)00165-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-020-02417-x","article-title":"Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease","volume":"472","author":"Chadt A","year":"2020","unstructured":"Chadt A, Al-Hasani H. Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease. Pflugers Arch. 2020, 472:1273-98. 10.1007\/s00424-020-02417-x","journal-title":"Pflugers Arch"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00944","article-title":"Discovery of PF-06835919: a potent inhibitor of ketohexokinase (KHK) for the treatment of metabolic disorders driven by the overconsumption of fructose","volume":"63","author":"Futatsugi K","year":"2020","unstructured":"Futatsugi K, Smith AC, Tu M, et al.. Discovery of PF-06835919: a potent inhibitor of ketohexokinase (KHK) for the treatment of metabolic disorders driven by the overconsumption of fructose. J Med Chem. 2020, 63:13546-60. 10.1021\/acs.jmedchem.0c00944","journal-title":"J Med Chem"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105375","article-title":"Nonalcoholic fatty liver disease (NAFLD). Mitochondria as players and targets of therapies?","volume":"22","author":"Di Ciaula A","year":"2021","unstructured":"Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic fatty liver disease (NAFLD). Mitochondria as players and targets of therapies?. Int J Mol Sci. 2021, 22:5375. 10.3390\/ijms22105375","journal-title":"Int J Mol Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00947","article-title":"Discovery of fragment-derived small molecules for in vivo inhibition of ketohexokinase (KHK)","volume":"60","author":"Huard K","year":"2017","unstructured":"Huard K, Ahn K, Amor P, et al.. Discovery of fragment-derived small molecules for in vivo inhibition of ketohexokinase (KHK). J Med Chem. 2017, 60:7835-49. 10.1021\/acs.jmedchem.7b00947","journal-title":"J Med Chem"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2021.04.007","article-title":"Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: a randomized phase 2 trial","volume":"2","author":"Kazierad DJ","year":"2021","unstructured":"Kazierad DJ, Chidsey K, Somayaji VR, Bergman AJ, Birnbaum MJ, Calle RA. Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: a randomized phase 2 trial. Med. 2021, 2:800-13.e3. 10.1016\/j.medj.2021.04.007","journal-title":"Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101196","article-title":"Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction","volume":"48","author":"Gutierrez JA","year":"2021","unstructured":"Gutierrez JA, Liu W, Perez S, et al.. Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction. Mol Metab. 2021, 48:101196. 10.1016\/j.molmet.2021.101196","journal-title":"Mol Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.892559","article-title":"Frontiers: Identifying candidate flavonoids for non-alcoholic fatty liver disease by network-based strategy","volume":"13","author":"Lee WY","year":"2022","unstructured":"Lee WY, Lee CY, Lee JS, Kim CE. Frontiers: Identifying candidate flavonoids for non-alcoholic fatty liver disease by network-based strategy. Front Pharmacol. 2022, 13:892559. 10.3389\/fphar.2022.892559","journal-title":"Front Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/331540-in-silico-analysis-of-saroglitazar-and-ferulic-acid-binding-to-human-ketohexokinase-implications-for-metabolic-dysfunction-associated-steatotic-liver-disease-masld","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T09:11:13Z","timestamp":1740215473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/331540-in-silico-analysis-of-saroglitazar-and-ferulic-acid-binding-to-human-ketohexokinase-implications-for-metabolic-dysfunction-associated-steatotic-liver-disease-masld"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.79437","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,22]]}}}